Syntara Expands Scar Treatment Study
Syntara will add 10 participants to the initial 20-patient Phase 1b study cohort of its topical anti-fibrotic drug candidate SNT-9465, developed to improve hypertrophic sternotomy scars.
Syntara will add 10 participants to the initial 20-patient Phase 1b study cohort of its topical anti-fibrotic drug candidate SNT-9465, developed to improve hypertrophic sternotomy scars.